Suscribirse

Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure - 28/08/11

Doi : 10.1016/S0002-9343(03)00085-8 
Richard D Swartz, MD a, , Leslie J Crofford, MD b, Sem H Phan, MD c, Robert W Ike, MD b, Lyndon D Su, MD c, d
a Division of Nephrology (RDS), Department of Internal Medicine, University of Michigan Health Systems, Ann Arbor, Michigan, USA 
b Rheumatology (LJC, RWI), Department of Internal Medicine, University of Michigan Health Systems, Ann Arbor, Michigan, USADepartments of 
c Department of Pathology (SHP, LDS), University of Michigan Health Systems, Ann Arbor, Michigan, USA 
d Department of Dermatology (LDS), University of Michigan Health Systems, Ann Arbor, Michigan, USA 

*Requests for reprints should be addressed to Richard D. Swartz, MD, Division of Nephrology, University of Michigan Health Systems, 3914 Taubman Center, Box 0364, Ann Arbor, Michigan 48109-0364, USA

Abstract

Background

Nephrogenic fibrosing dermopathy is a newly recognized cutaneous fibrosing disorder marked by the acute onset of induration involving the upper and lower limbs in patients with acute or chronic renal failure. The etiology, pathogenesis, associated clinical conditions (other than renal failure), and ultimate course have not been defined in the few cases studied. Presently, there is no effective treatment, and the condition persists in most patients.

Methods

Clinical and histopathologic data on 13 patients from our institution with the diagnosis of nephrogenic fibrosing dermopathy were reviewed. Several clinical and laboratory parameters were examined to see if any were consistently associated with the disease. Biopsy specimens were analyzed to determine if there was a pattern to the evolution of fibrosis in these patients.

Results

All 13 patients had renal failure before disease onset: 8 were undergoing chronic hemodialysis, 2 were undergoing chronic peritoneal dialysis, and 3 with acute renal failure had never undergone dialysis before the development of dermopathy. Most patients had other serious underlying medical conditions. Many patients were taking erythropoietin, cyclosporine, or both before the onset of disease. In transplant patients, no histocompatibility antigens were found to be associated with the disease. There were various laboratory abnormalities, but none were consistently associated with the condition. In skin biopsy specimens taken 7 to 180 days after disease onset, there were histopathologic changes suggestive of a tissue reaction to injury, as well as the development of smooth muscle actin–positive myofibroblasts.

Conclusion

Nephrogenic fibrosing dermopathy is a novel cutaneous fibrosing disorder that is distinguished from other sclerosing or fibrosing skin disorders by distinctive clinical and histopathologic findings occurring in the setting of renal failure. There were no additional clinical risk factors or laboratory findings common to the 13 patients studied, other than renal failure. The resemblance to a tissue injury reaction and the presence of myofibroblasts in the tissue specimens suggest that fibrogenic cytokines may be involved in the evolution of the disease.

El texto completo de este artículo está disponible en PDF.

Esquema


© 2003  Excerpta Medica Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 114 - N° 7

P. 563-572 - mai 2003 Regresar al número
Artículo precedente Artículo precedente
  • Intensive smoking cessation counseling versus minimal counseling among hospitalized smokers treated with transdermal nicotine replacement: a randomized trial
  • Joel A Simon, Timothy P Carmody, Esther S Hudes, Elizabeth Snyder, Jana Murray
| Artículo siguiente Artículo siguiente
  • Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection
  • Joan S Tucker, M.Audrey Burnam, Cathy D Sherbourne, Fuan-Yue Kung, Allen L Gifford

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.